- 智通财经APP | 2024年02月26日 08:50调研机构Precedence Research:放射性药物市场规模到2032年预计将增至约140亿美元
- 智通财经APP | 2023年09月11日 08:53美股生物医药股如何买?汇丰新鲜名单出炉
- finviz | 2022年09月26日 19:30Actinium to Present at the Cantor Fitzgerald Oncology, Hematology & HemeOnc Conference
- finviz | 2022年09月21日 19:30Actinium Pharmaceuticals Announces Iomab-B SIERRA Trial Database Lock, Provides Corporate Update Highlighting Key Upcoming Milestones
- finviz | 2022年09月09日 01:50With Upcoming Pivotal Data, Analyst Sees 145% Upside In Actinium
- finviz | 2022年09月08日 19:00Actinium Pharmaceuticals to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
- finviz | 2022年08月15日 22:15CV Sciences, Inc. (CVSI) Reports Q2 Loss, Lags Revenue Estimates
- finviz | 2022年08月11日 20:55Marinus Pharmaceuticals (MRNS) Reports Q2 Loss, Lags Revenue Estimates
- finviz | 2022年08月10日 06:25Organogenesis (ORGO) Tops Q2 Earnings and Revenue Estimates
- finviz | 2022年08月04日 19:35Aurinia Pharmaceuticals (AUPH) Reports Q2 Loss, Tops Revenue Estimates
- finviz | 2022年05月19日 21:40Has Alkermes (ALKS) Outpaced Other Medical Stocks This Year?
- finviz | 2022年04月25日 19:30Actinium Pharmaceuticals, Inc. Announces 82% of Control Arm Patients Did Not Receive a Bone Marrow Transplant by Conventional Means but 100% of Patients who Received Iomab-B, Including Crossover Patients, in the Phase 3 SIERRA Trial Successfully Engrafted
- finviz | 2022年04月19日 19:30Actinium Pharmaceuticals, Inc. to Highlight Iomab-B Pivotal Phase 3 SIERRA Trial Data at the Transplantation & Cellular Therapy Tandem Meetings of ASTCT and CIBMTR
- finviz | 2022年04月14日 03:36Actinium (ATNM) Up on Commercialization Deal With Immedica
- finviz | 2022年04月12日 19:00Actinium Pharmaceuticals, Inc. and Immedica Announce Commercialization Agreement for Iomab-B (131I apamistamab) in Europe, the Middle East and North Africa
- finviz | 2022年04月11日 19:37Actinium Pharmaceuticals Highlights Potent Anti-Tumor Activity of a HER3 Targeted Radiotherapy at AACR